Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013687" target="_blank" >RIV/00023736:_____/24:00013687 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15110/24:73626354 RIV/00098892:_____/24:10158761

Result on the web

<a href="https://doi.org/10.1016/j.htct.2024.03.010" target="_blank" >https://doi.org/10.1016/j.htct.2024.03.010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.htct.2024.03.010" target="_blank" >10.1016/j.htct.2024.03.010</a>

Result language

angličtina

Original language name

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Original language description

A lower dosage of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukaemia (CML) has shown efficacy in managing short-term toxicity and maintaining a deep molecular response in patients who fail to achieve treatment-free remission. From over 700 patients with CML who were treated at two centres over the last three decades, this retrospective study identified eight patients characterised by long-term treatment failure and simultaneous prolonged significant haematologic toxicity that prevented the use of the standard tyrosine kinase inhibitor dosage. It is important not to stop treatment with tyrosine kinase inhibitors at a low personalised dosage in CML patients with prolonged significant haematologic toxicity despite long-term treatment failure.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Hematology transfusion and cell therapy

ISSN

2531-1379

e-ISSN

—

Volume of the periodical

46

Issue of the periodical within the volume

6

Country of publishing house

BR - BRAZIL

Number of pages

11

Pages from-to

"S171"-"S181"

UT code for WoS article

001392017600001

EID of the result in the Scopus database

2-s2.0-85199961204